{"title":"安进诉赛诺菲案：美国最高法院审查专利实施情况","authors":"Gregory Curfman, Marcia M. Boumil","doi":"10.1017/jme.2023.102","DOIUrl":null,"url":null,"abstract":"<p>On June 18, 2023, the U.S. Supreme Court in the matter of <span>Amgen, Inc. et al. v. Sanofi, et al.</span><span>1</span> unanimously upheld the 2021 decision of the U.S. Court of Appeals for the Federal Circuit,<span>2</span> striking down as overbroad Amgen’s patent claim to an entire functional genus of monoclonal antibodies. Amgen’s patent claims were not limited to antibody structure or <span>antibody</span> amino acid sequences. This is significant because Amgen’s patent claims did have amino acid sequences, but they were directed to the epitope.</p>","PeriodicalId":501694,"journal":{"name":"The Journal of Law, Medicine & Ethics","volume":"96 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Amgen v. Sanofi: The U.S. Supreme Court Reviews Patent Enablement\",\"authors\":\"Gregory Curfman, Marcia M. Boumil\",\"doi\":\"10.1017/jme.2023.102\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>On June 18, 2023, the U.S. Supreme Court in the matter of <span>Amgen, Inc. et al. v. Sanofi, et al.</span><span>1</span> unanimously upheld the 2021 decision of the U.S. Court of Appeals for the Federal Circuit,<span>2</span> striking down as overbroad Amgen’s patent claim to an entire functional genus of monoclonal antibodies. Amgen’s patent claims were not limited to antibody structure or <span>antibody</span> amino acid sequences. This is significant because Amgen’s patent claims did have amino acid sequences, but they were directed to the epitope.</p>\",\"PeriodicalId\":501694,\"journal\":{\"name\":\"The Journal of Law, Medicine & Ethics\",\"volume\":\"96 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Law, Medicine & Ethics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1017/jme.2023.102\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Law, Medicine & Ethics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1017/jme.2023.102","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
2023年6月18日，在Amgen, Inc. et al. v. Sanofi, et al.一案中，美国最高法院一致支持美国联邦巡回上诉法院2021年的判决，2驳回了Amgen对整个单克隆抗体功能属的专利要求，认为其过于宽泛。安进的专利权利要求并不局限于抗体结构或抗体氨基酸序列。这是很重要的，因为安进的专利要求确实有氨基酸序列，但它们是指向表位的。
Amgen v. Sanofi: The U.S. Supreme Court Reviews Patent Enablement
On June 18, 2023, the U.S. Supreme Court in the matter of Amgen, Inc. et al. v. Sanofi, et al.1 unanimously upheld the 2021 decision of the U.S. Court of Appeals for the Federal Circuit,2 striking down as overbroad Amgen’s patent claim to an entire functional genus of monoclonal antibodies. Amgen’s patent claims were not limited to antibody structure or antibody amino acid sequences. This is significant because Amgen’s patent claims did have amino acid sequences, but they were directed to the epitope.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
